KR950016741A - 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법 - Google Patents
체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법 Download PDFInfo
- Publication number
- KR950016741A KR950016741A KR1019940034932A KR19940034932A KR950016741A KR 950016741 A KR950016741 A KR 950016741A KR 1019940034932 A KR1019940034932 A KR 1019940034932A KR 19940034932 A KR19940034932 A KR 19940034932A KR 950016741 A KR950016741 A KR 950016741A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- weight loss
- hydrochloride
- curb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000004580 weight loss Effects 0.000 title claims abstract 3
- 230000004584 weight gain Effects 0.000 title abstract 2
- 235000019786 weight gain Nutrition 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 3
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- -1 pyrrolidino, hexamethyleneimino Chemical group 0.000 claims abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/171,291 | 1993-12-21 | ||
| US08/171,291 US5578613A (en) | 1993-12-21 | 1993-12-21 | Methods for inhibiting weight gain or inducing weight loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950016741A true KR950016741A (ko) | 1995-07-20 |
Family
ID=22623225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940034932A Withdrawn KR950016741A (ko) | 1993-12-21 | 1994-12-19 | 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5578613A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0659423A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH07196492A (cg-RX-API-DMAC7.html) |
| KR (1) | KR950016741A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1107707A (cg-RX-API-DMAC7.html) |
| AU (1) | AU8154094A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2138455A1 (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ322294A3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUT71342A (cg-RX-API-DMAC7.html) |
| IL (1) | IL112044A (cg-RX-API-DMAC7.html) |
| NO (1) | NO944923L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ270182A (cg-RX-API-DMAC7.html) |
| PH (1) | PH31266A (cg-RX-API-DMAC7.html) |
| RU (1) | RU94044357A (cg-RX-API-DMAC7.html) |
| TW (1) | TW272126B (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA9410090B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417198B1 (en) | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US5900418A (en) * | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
| EA200100039A1 (ru) | 1998-06-16 | 2001-06-25 | Эли Лилли Энд Компани | Способы увеличения уровней ацетилхолина |
| IL146284A0 (en) | 1999-05-04 | 2002-07-25 | Strakan Ltd | Androgen glycosides and pharmaceutical compositions containing the same |
| US20060088860A1 (en) * | 2004-09-13 | 2006-04-27 | Lipomics Technologies, Inc. | Metabolite markers for weight management |
| CA2588087A1 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| EP2225261B1 (en) | 2007-12-03 | 2016-03-09 | Obe Therapy Biotechnology | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
| US20140378424A1 (en) * | 2011-12-30 | 2014-12-25 | Rosscreening, Inc. | Estrogen receptor modulators for reducing body weight |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| TW303299B (cg-RX-API-DMAC7.html) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli |
-
1993
- 1993-12-21 US US08/171,291 patent/US5578613A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 RU RU94044357/14A patent/RU94044357A/ru unknown
- 1994-12-19 EP EP94309481A patent/EP0659423A1/en not_active Withdrawn
- 1994-12-19 CZ CZ943222A patent/CZ322294A3/cs unknown
- 1994-12-19 HU HU9403673A patent/HUT71342A/hu unknown
- 1994-12-19 IL IL11204494A patent/IL112044A/en not_active IP Right Cessation
- 1994-12-19 PH PH49576A patent/PH31266A/en unknown
- 1994-12-19 JP JP6314559A patent/JPH07196492A/ja active Pending
- 1994-12-19 AU AU81540/94A patent/AU8154094A/en not_active Abandoned
- 1994-12-19 NZ NZ270182A patent/NZ270182A/en unknown
- 1994-12-19 NO NO944923A patent/NO944923L/no unknown
- 1994-12-19 ZA ZA9410090A patent/ZA9410090B/xx unknown
- 1994-12-19 TW TW083111849A patent/TW272126B/zh active
- 1994-12-19 CA CA002138455A patent/CA2138455A1/en not_active Abandoned
- 1994-12-19 CN CN94119748A patent/CN1107707A/zh active Pending
- 1994-12-19 KR KR1019940034932A patent/KR950016741A/ko not_active Withdrawn
-
1995
- 1995-03-15 US US08/404,854 patent/US5578614A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU8154094A (en) | 1995-06-29 |
| HU9403673D0 (en) | 1995-02-28 |
| CN1107707A (zh) | 1995-09-06 |
| US5578614A (en) | 1996-11-26 |
| TW272126B (cg-RX-API-DMAC7.html) | 1996-03-11 |
| JPH07196492A (ja) | 1995-08-01 |
| HUT71342A (en) | 1995-11-28 |
| CA2138455A1 (en) | 1995-06-22 |
| PH31266A (en) | 1998-06-18 |
| NO944923D0 (no) | 1994-12-19 |
| US5578613A (en) | 1996-11-26 |
| EP0659423A1 (en) | 1995-06-28 |
| NO944923L (no) | 1995-06-22 |
| RU94044357A (ru) | 1996-10-20 |
| NZ270182A (en) | 1996-08-27 |
| CZ322294A3 (en) | 1995-09-13 |
| ZA9410090B (en) | 1996-06-19 |
| IL112044A (en) | 1999-01-26 |
| IL112044A0 (en) | 1995-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950016738A (ko) | 알쯔하이머 질병의 억제 방법 | |
| KR950016732A (ko) | 피부 및 질의 위축 억제방법 | |
| KR950010893A (ko) | 자궁내막증 억제 방법 | |
| KR950016744A (ko) | 트롬빈을 저해하는 방법 | |
| KR950016725A (ko) | 폐 고혈압성 질병을 억제하는 방법 | |
| KR950010892A (ko) | 자궁 섬유증 억제 방법 | |
| KR950016731A (ko) | 지루 및 좌창의 억제 방법 | |
| KR950010890A (ko) | 폐경기 증후군의 치료방법 | |
| KR950016746A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
| KR940005270A (ko) | 뼈 손실 예방에 유용한 벤조티오펜 | |
| RU97108050A (ru) | Способ ингибирования состояний, связанных с нейропептидом y | |
| KR970706818A (ko) | 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) | |
| KR950016723A (ko) | 자가면역 질병의 억제 방법 | |
| KR950016724A (ko) | 폐경기 후 여성의 리비도를 증가시키는 방법 | |
| KR950016730A (ko) | 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 | |
| KR950010887A (ko) | 연골 퇴화 억제 방법 | |
| KR950010889A (ko) | 혈관형성 및 혈관형성성 질병을 억제하는 방법 | |
| KR950016726A (ko) | 기능부전성 자궁 출혈을 억제하는 방법 | |
| KR950010891A (ko) | 내성 종양을 치료하는 방법 | |
| KR950016722A (ko) | Ldl 산화 및 죽상동맥경화증의 억제 방법 | |
| KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
| KR950016742A (ko) | 폐경후 여성의 씨엔에스 질환을 억제하는 방법 | |
| KR950016734A (ko) | 성적 조숙증의 억제방법 | |
| KR950016735A (ko) | 터너 증후군의 억제 방법 | |
| KR950016729A (ko) | 유방 질환의 억제 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19941219 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |